Just this morning, Moderna (MRNA) was downgraded by JP Morgan on valuation concerns.
In fact, analyst Cory Kasimov said that while he is bullish on the stock, MRNA can no longer support the stock’s valuation.
On that news, MRNA fell $10. However, the pullback may not last long thanks to strong COVID-19 study results. Remember, not only ago, MRNA announced its vaccine was found to induce immune responses in every volunteer in a Phase 1 study.
“These early results, published in the New ...
Already a member? Login below, or click here to register now for free.